# Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

> **NCT01336933** · PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 34 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** prednisone
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **DRUG:** Vincristine
- **DRUG:** pralatrexate
- **OTHER:** laboratory biomarker analysis
- **GENETIC:** comparative genomic hybridization
- **GENETIC:** gene expression analysis
- **GENETIC:** nucleic acid sequencing
- **GENETIC:** mutation analysis
- **OTHER:** immunohistochemistry staining method
- **GENETIC:** microarray analysis
- **GENETIC:** RNA analysis

## Key facts

- **NCT ID:** NCT01336933
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-06
- **Primary completion:** 2016-12-28
- **Final completion:** 2016-12-28
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-09-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01336933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01336933, "Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01336933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*